November 29, 2018, Medscape  

A novel test engineered from a bacterial toxin has been shown to detect significant levels of a specific biomarker released into the blood by ovarian cancer cells at all stages of the disease, including the early stages, distinguishing patients with ovarian cancer from healthy unaffected controls, research indicates. 

Read more.